Anti-viral drug treatment of infections with the human immunodeficiency virus type 1 (HIV-1) usually leads to a rapid decline in the abundance of plasma virus. The effect of single drug therapy, however, is often only short-lived as the virus readily develops drug-resistant mutants. In this paper we provide analytic approximations for the rate of emergence of resistant virus. We study the decline of wildtype virus and the rise of resistant mutant virus in different compartments of the virus population such as free plasma virus, cells infected with actively replicating virus, long-lived infected cells and cells carrying defective provirus. The model results are compared with data on the rise of drug-resistant virus in three HIV-1 infected patients treated with neverapine (NVP). We find that the half-life of latently infected cells is between 10 and 20 days, whereas the half-life of cells with defective provirus is about 80 days. We also provide a crude estimate for the basic reproductive ratio of HIV-1 during NVP therapy.
Introduction
In recent years, a number of anti-viral drugs have been developed that are potent inhibitors of HIV-1 replication in vivo. The two major types of anti-HIV drugs are reverse transcriptase inhibitors and protease inhibitors. Reverse transcriptase inhibitors prevent the infection of new cells by blocking the reverse transcription of the HIV RNA into DNA, which would integrate into the host cell genome. Protease inhibitors prevent already infected cells from producing infectious virus particles.
Treatment with either type of drug leads to a rapid decline in plasma virus and an increase in CD4 cells, which constitute the major target cell of HIV infection. Monitoring the rate of virus decline in the first few days of treatment leads to interesting insights into the short-term dynamics of HIV infection. Most of the plasma virus is produced by HIV-infected cells that have a half-life of about 2 days (Ho et al., 1995; Wei et al., 1995; Coffin, 1995; Nowak et al., 1995; Perelson et al., 1996) . The half-life of free virus particles has been estimated to be about 6 hr and the time-span between infection of a cell and production of new virus particles to be around 0.9 days (Perelson et al., 1996) . The latter estimates rely on a detailed kinetic understanding of the initial shoulder of virus decline within 48 hr after start of therapy and are therefore problematic (Herz et al., 1996) .
Prolonged treatment with a single anti-HIV drug almost always results in the emergence of resistant virus (Larder et al., 1989 (Larder et al., , 1993 (Larder et al., , 1995 Larder & Kemp, 1989; Richman, 1990 Richman, , 1994 Richman et al., 1994; St Clair et al., 1991; Ho et al., 1994; Loveday et al., 1995; Markowitz et al., 1995) . In AZT treatment, a number of mutations have been described that render the virus more and more resistant against the drug (Boucher et al., 1990 (Boucher et al., , 1992a Mohri et al., 1993; de Jong et al., 1996) . In NVP and 3TC treatment, single point mutations appear to confer high level resistance against the drug (Richman et al., 1994; Schuurman et al., 1995; Wei et al., 1995) . Much hope is currently being offered by combining several different anti-HIV drugs. Simultaneous treatment with AZT and 3TC, for example, can suppress virus load about ten-fold in patients treated for up to 1 year (Eron et al., 1995; Staszewski, 1995) . Preliminary data on treatment with AZT, 3TC and a protease inhibitor suggest that virus load can be suppressed to undetectable levels (about a 10000-fold reduction) and stays below detection limit in patients treated for several months (David Ho, Douglas Richman, personal communication) .
Mathematical models have been developed to describe the population dynamics of virus replication following drug treatment and the emergence of resistant mutant. McLean et al. (1991) proposed that the short term effect of AZT treatment is due to the predator-prey like interaction between virus and host cells, and that the CD4 cell increase following drug treatment is responsible for the resurgence of virus even in the absence of resistant mutants. Nowak et al. (1991) study the effect of drug treatment on delaying progression to disease. McLean & Nowak (1992) postulate that the rise of drug-resistant virus is caused by the increase in available target cells for HIV infection. Frost & McLean (1994) and McLean & Frost (1995) describe models for the sequential emergence of resistant variants in AZT therapy. Wein et al. (1996) use a control theoretic approach for multidrug therapies. Kirschner & Webb (1996) study the emergence of drug resistant virus in a model with CD4 and CD8 cells. De Boer & Boucher (1996) propose that reducing CD4 cell numbers can potentially prevent the emergence of drug-resistant virus.
In this paper we develop analytic solutions for the emergence of resistant virus under single drug therapy. We will describe the rate of increase of resistant virus in the free virus population and in the infected cell population and show how the model can be used to estimate demographic parameters of virus population dynamics in vivo.
In Section 2 we outline the basic model of virus dynamics, in Section 3 we discuss the initial viral decline after start of therapy and in Section 4 we derive analytic approximations for the rise of resistant mutant. In Section 5 we expand the basic model to include cells that harbour latent or defective virus. We present clinical data on three patients treated with NVP in Section 6 and conclude in Section 7.
The Basic Model
In the basic model of viral dynamics we distinguish three variables: uninfected cells x, infected cells y, and virus particles v. Let us assume that uninfected cells are produced at a constant rate, l, from a pool of precursor cells and die at rate dx. This is the simplest possible host cell dynamics. Later we will discuss more complex assumptions. Virus reacts with uninfected cells to produce infected cells. This happens at rate bxv. Infected cells die at rate ay. Virus is produced from infected cells at rate ky and dies at rate uv. This gives rise to the following system of ordinary differential equations:
If the basic reproductive ratio of the virus,
is larger than one, then the system converges to the equilibrium
Viral Decline Under Drug Therapy
Let us assume that the virus infection is in equilibrium (steady state) as specified by eqn (3). We are interested in the decline of free virus and infected cells and the rise of uninfected cells following drug treatment. If a drug prevents the infection of new cells (i.e. b = 0) then the equations become
subject to the initial conditions x*, y*, and v* at t = 0. This gives rise to the following solutions:
The initial slope of the rise of uninfected cells is simply l − dx*. Thus for the same value of l and d, patients with low x* should have the higher initial decrease. The rise of uninfected cells in the absence of viral resurgence would then level out converging to the uninfected equilibrium, x = l/d.
Infected cells fall purely as an exponential function of time. In the applications we have in mind, u is much larger than a (u a). For this case, virus density does not begin to fall significantly until t 1 1/u, and thereafter falls as e −at (if a u the converse of course is true).
Emergence of Resistant Mutant Under Drug Therapy
In HIV-1 infection there is rapid development of resistant virus to all known drugs. Often a single point mutation can greatly reduce sensitivity to a particular drug. In this section we calculate the rate at which the abundance of a resistant mutant rises. Before drug therapy the resistant mutant virus is held in a mutation-selection balance. It is continuously generated by the sensitive wildtype, but has a slight selective disadvantage. (If it did not have a selective disadvantage it would already dominate the virus population before therapy is given. This is not observed.) An appropriate system that describes this mutation-selection process is the following:
Here y m describes cells infected by mutant virus, whereas v m denotes mutant virus particles. The parameter e denotes the probability of mutation from wildtype to resistant mutant during reverse transcription of viral RNA into proviral DNA. If wildtype and mutant differ by a single point mutation then e will be within 10 −3 -10 −5 . We can neglect back mutation from mutant to wildtype because (before therapy) the population is dominated by wildtype virus. We assume that wildtype and mutant may differ in their rates at which they infect new cells, b and b m , and the rates at which infected cells produce virus, k and k m . In the absence of drug treatment the wildtype has a higher basic reproductive ratio (i.e. fitness) which imples bk q b m k m . This condition specifies that selection favours wildtype virus. The steady state of (8) 
We want to solve this system subject to the initial conditions (9), the steady state before drug treatment. Wildtype virus and infected cells decline as before; given by eqns (6) and (7). If the decay rate of free virus is much larger than the decay rates of infected and uninfected cells (u a, d) , then to a good approximation we may assume that v m = (k m /u)y m and the equations for the rise of resistant mutant become
We rescale xˆ= (d/l)x, yˆm = y m b m /(du) and obtain
Here we have defined
That is R m is the basic reproductive ratio of the mutant resistant viral strain (we have used R m , rather than the double subscripted R 0m , to avoid notational complexity in the expressions which follow). It is further useful to define
The rescaled initial conditions are now-using eqns (2) and (3)-
Here eˆis defined (neglecting terms of relative order e) as
The solutions of system (12) follow along the lines of a similar mathematical system for the spread of infectious diseases in populations as analysed in Appendix C of Anderson & May (1991) . There are two phases for the rise in resistant mutant. As long as yˆm is small compared to one, the system is approximately
We have
7%
. (19) Interestingly the resistant mutant, yˆm (t), falls initially, because its abundance is at first still roughly set by the equilibrium in a mutation-selection balance. As the mutuational influx from the wildtype disappears, because the drug stops wildtype replication, the mutant falls, because the uninfected cell population is at a level too low to maintain the mutant. But eventually the rise in the uninfected cell population, xˆ(t), causes the resistant mutant to increase (once R m xˆq 1). Note that resistant mutant virus grows only because the uninfected cell population increases. Phase I ends when yˆm (t) becomes of order unity, which for small f is (very) approximately at t = 2/(R m d); for details of the analysis, see Anderson & May (1991, appendix C) . In phase II there is exponential growth of yˆm (t), essentially on a 1/a timescale. Correspondingly xˆ(t) will fall, and yˆm (t) will peak when yˆ m = 0 or xˆ(t) = 1/R m . At this point, xˆ(t) is still decreasing, so yˆm (t) will now fall (still on the time scale of 1/a at first), until xˆ(t) ceases to decline when xˆ= 1/ (1 + yˆm ). At this point yˆm will be enough below unity that xˆclimbs again, but R m xˆQ 1 and yˆm continues to fall. Eventually (time scale 1/d)xˆ(t) will climb back to R m xˆq 1, whereafter yˆm (t) will rise and the cycle repeats. There are slowly damped oscillations eventually leading to the equilibrium xˆ= 1/R m and yˆm = R m − 1. The damping time-scale is of the order of t d = 2/(R m d); in the later stages there are low amplitude oscillations of period t osc = 2p/zad(R m − 1).
In order to extract information about the ''demographic'' (birth and death) parameters in eqns (8) from the available data, next we calculate the rise of resistant mutant in terms of the relative proportions of mutants among the populations of infected cells or free virus. The proportions of mutants in both these categories will rise, converging to essentially 100% during phase I of the dynamics. If R m is significantly larger than unity, so that dt Q 1 throughout phase I, eqn (19) can be Taylor-expanded to give
. (20) Let us define f(t) = y m (t)/y(t), where y m and y now refer to the absolute values, before any rescaling. We have, using eqn (16),
The relative proportion of mutant virus among the infected cells is then
Similarly, the fraction of mutant in the free virus population is
If k = k m , which means that wildtype and mutant do not differ in the rate at which infected cells produce virus, then the rise of mutant in the free virus and infected cell populations occurs simultaneously. If k q k m then the mutant rises first in the infected cell population. If k Q k m (which is possible but unlikely, because the wildtype is expected to have a higher fitness) then the mutant rises first in the free virus population.
In particular, the time at which the mutant virus constitutes 50% of all infected cells, t y , is given by the solution of
with f(t) defined by eqn (21). Under the approximation of eqn (21), t y is given by the solution of the quadratic equation
For specified values of the parameters R m , f, a, d, and e, the solution is routine. In the limit when R m is significantly greater than f, a significantly larger than d (infected cells live less long than uninfected ones), and e 1, we have the approximate solution
. (27) Likewise, the time at which the mutant virus represents 50% of all free virus, t v , is given by f(t v ) = k/k m . The approximate results of eqns (26) and (27) again pertain, except now e is replaced by ek m /k in the argument of the logarithmic term.
Finally, the difference between the times when the mutant virus constitutes 50% of all infected cells, and 50% of all free virus, D = t y − t v , is given under the approximation of the quadratic equation (25) for t y , and its analogue for t v , as:
Thus, empirical observations of t y and t v enable us to make inferences about the rate constants. In particular, eqn (25) or (27) may be used to obtain a rough estimate on the basic reproductive ratio, R m , of the mutant under drug therapy. It must be kept in mind that this analysis is based on the assumption that t y and t v are both attained during ''phase I'' of the mutant virus' dynamics (i.e., with yˆm (t) Q 1); in any applications, either to understanding simulations or analysing real data, the validity of this approximation should be checked for consistency, once inferences have been drawn. Figure 1 shows the dynamics of the emergence of drug-resistant virus in the basic model. In the simulation it takes about 9.7 days for the resistant virus to reach 50% prevalence in the infected cell population. This agrees well with a prediction of 10.1 days from the analytic approximation given by eqn (27).
Different Types of Infected Cells
In HIV infected individuals, large proportions of infected cells do not produce new virus particles. These cells can either harbour replication competent virus which is in a latent state, waiting to be reactivated, or defective virus which is unable to complete its life cycle. In addition, there are long-lived infected cells which continuously produce a small amount of new virus particles. Therefore, we now expand the basic system (7) by including populations of long-lived infected cells that harbour latent (or chronically producing) virus and defective virus, as distinct from those with actively replicating virus. Let y 1 , y 2 , and y 3 denote infected cells that contain actively replicating virus, latent virus, and defective virus, respectively. We obtain
The parameter q i describes the probability that upon infection a cell will enter type i; S q i = 1. Thus q 1 is the probability that the cell will immediately enter active viral replication; y 1 cells will produce virus at rate k. The parameter q 2 is the probability that the cell will become latently infected with the virus and produce virus at a much slower rate c. In terms of this model, latent cells are in fact slow chronic producers of free virus. The parameter q 3 specifies the probability that infection of a cell produces a defective provirus that will not produce any offspring virus. The decay rates of actively producing cells, latently infected cells and defectively infected cells are a 1 , a 2 , and a 3 , respectively. From previous studies (Wei et al., 1995) we know that a 1 is around 0.4 per day and a 3 around 0.01 per day. We expect a 2 to lie between these two values. The death rate of uninfected cells, d, will be similar to a 3 (probably slightly smaller). Provided the basic reproductive ratio of the wildtype,
is larger than one, the system converges to the equilibrium
where
The similarities with, and differences from, the preceeding Basic Model are as we would expect. 
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During drug therapy (b = 0), wildtype virus will, as before, decline exponentially in the individual types of infected cells
Free wildtype virus particles decay according to
. (34) If u is sufficiently larger than the other decay constants, then a good approximation is
We know that free virus declines with a half-life of about 2 days (Wei et al., 1995; Ho et al., 1995; Nowak et al., 1995) and hence the leading term of viral decay has to be the a 1 -exponential decline. Therefore, we conclude that most of the free plasma virus is produced by actively replicating cells. Latently F. 1. A computer simulation of the basic model [eqn (8)] describing the rise of resistant mutant virus during drug therapy. Uninfected cells rise initially almost linearly with time. Wildtype virus declines exponentially with rate a both in terms of infected cells and free virus. Resistant mutant initially declines compared to its pretreatment steady state, but then rises rapidly as a consequence of an increase in uninfected cell numbers. Subsequently uninfected cells decline and the system converges to a new steady state with the virus population consisting entirely of resistant mutant. Note that new and old steady state have essentially equivalent x, y and v values, even if the replication rate of the resistant virus during drug therapy is much lower than the replication rate of wildtype virus before therapy. Parameter values are l = 10, d = 0.01, a = 0.5, u = 3, b = 0.01, bm = 0.005, e = 0.0001, k = km = 10 per day. This implies that the average life times of uninfected cells, infected cells and free virus are, respectively, 100, 2 and 0.333 days. The basic reproductive ratio of wildtype virus before treatment is R0 = 66.6 and of resistant virus during treatment is Rm = 33.3. In the simulation it takes about ty = 9.7 days for the resistant virus to increase to a relative frequency of 50% in the infected cell population. Using eqn (27) of our analytical approximation, we obtain ty = 10.1 days; the exact solution of the quadratic eqn (25) suggests ty = 8.8 days. infected cells can only contribute a little to the plasma virus pool; in mathematical terms we must have ky* 1 cy* 2 .
The full dynamics, including drug-resistant strains, is described by the following system: 
For a small mutation rate, e (and a basic reproductive ratio larger than one), the mutant virus and its infected cells are initially present at their low, mutation-selection levels, given by putting all time derivatives equal to zero in eqn (36). Neglecting relative order e, we get:
Here we have, in analogy with the Basic Model, defined
with R 0 defined by eqns (30) and (32), and R m defined correspondingly as
Paralleling eqn (32), A m is defined as
The quantities x*, v*, y* i are defined as above, in eqns (31). These results are straightforward extensions of those for the earlier Basic Model. We now turn to analyse the dynamics of the rise of resistant mutant virus populations, and their infected cells, following the sustained administration of drug after t = 0; that is, we look at eqns (36) with b = 0 for t e 0. For the following calculations we shall assume that most of the free virus is produced by the active rather than the latent cell pool. Thus, from now on, we neglect cy 2 compared with ky 1 , and similarly for the mutant. This reasonable approximation will greatly reduce the complexity of our analysis, permitting insight into the numerical simulations.
With b = 0, and c = c m = 0, the dynamics of the mutant virus and the cells it infects are given, for t q 0, by
As before, we assume the viral turn-over rate, u, is significantly faster than other rate constants, so that the mutant virus dynamics tracks that of y 1m :
It is apparent that the dynamics of x(t) and y 1m (t) are again described by the pair of equations given earlier as eqn (12):
The rescaling is exactly as in eqn (12), and R m is defined by eqn (39) which, for c m = 0, is
In eqn (43), the initial conditions are again given by eqn (15). 
For the pool of cells latently infected with resistant mutant virus, y 2m (t), we have the equation
This can be integrated to get
On the r.h.s., the first term is initially of order e, and thereafter decreases; the second term begins of order e, but increases. Henceforth we neglect this first term on the r.h.s. Similarly, from eqn (41) we obtain for the population of defectively infected cells the approxi- Alternatively, expressed in terms of the rescaled xˆand yˆ1 m of eqn (43), we have
We conclude this section with remarks on the characteristic dynamics of each of the populations of cells, y 1m , y 2m , and y 3m . We refer both to absolute abundance, and-in analogy to the discussion of the Basic Model-to abundance relative to (declining) populations of corresponding cells infected with the wildtype virus. The discussion is illustrated with reference to the numerical simulations of Fig. 2 . Our main purpose, however, is to gain qualitative insights which may help us extract information about vital rates from empirical data on temporal abundance of uninfected and different types of infected cells.
(
i) Uninfected cells, x(t).
With b = 0 for t q 0, we expect x(t) to rise (at first roughly linearly, x(t) 1 x* + lt(1 − 1/R 0 ) + O(t 2 )) during phase I. Eventually, x(t) will damp to its asymptotic value at x* m = 1/R m .
(ii) Infected cells, actively producing resistant mutant virus, y 1m (t). Here we have eqn (5) as an approximate description of y 1m (t) throughout ''phase I'', where yˆ1 m = (b m k m /du)y 1m Q 1. Thereafter, y 1m (t) rises further on a fast, 1/a 1 , time-scale, and subsequently falls and further executes damped oscillations, toward an asymptotic value of y 1m (a) = (q 1 l/a 1 )(1 − 1/R m ).
From a practical point of view, this suggests that we can estimate l from the early (roughly linear) slope of the x(t) vs t data, and thence estimate q 1 /a 1 from the asymptotic value of y 1m (t 4 a) (assuming 1/R m is smallish compared with unity).
For an estimate of Y 1 (t), the fraction of mutant-infected cells among the totality of activelyreplicating infected cells, we again have eqn (22),
Here f 1 (t) = y 1m (t)/y 1 (t) is again given essentially by eqn (21), except a 1 replaces a, and R m is given by eqn (44). The 50% point is thus again given by eqn (25): Notice also in this example that k m = k, whence the mutant virus-expressed as a proportion of total virus-rises almost exactly as fast as do activelyreplicating infected cells. More generally, if k m Q k, we would see mutant virus, expressed proportionately [the V of eqn (23)], rising later than actively-replicating infected cells (the Y 1 defined above).
(iii) Defectively infected cells, y 3m (t). Initially, the ratio y 3m (0)/y 3 (0) is e/(1 − f ), as given by eqn (31). More generally, we can write the proportion of mutant-infected cells among all defectively-infected cells as
Here f 3 (t) is defined, from the good approximation of eqn (49), as
Remember, xˆ (0)yˆ1 
For small t, f 3 is of order e. For very large t, a 3 t 1, the non-exponential part of the integrand will asymptote to the value xˆ(t)yˆ1 m (t) 4 1 − 1/R m ; thence for a 3 t 1 we get
The passage from f 3 1 e to f 3 1 is, however, complex and dependent on the relative time scales involved. We have already assumed that the turn-over (death) rate of free virus is the fastest rate in the system (u a i and d). We have also earlier assumed that virus-producing cells live significantly shorter than uninfected cells (a 1 d). We now further explore the case where the death rate of defectively-infected cells, y 3 , are comparable with uninfected ones, with latent cells, y 2 , having intermediate death rates: u a 1 q a 2 a 3 1 d. These assumptions seem biological reasonable. They appear to accord roughly with the available data on HIV infection, and they pertain to the numerical simulations of Fig. 2 . Under these assumptions, in the extreme limit where a 3 and d are so much slower than a 1 that we can regard xˆand yˆ1 m as moving to their long-term equilibrium values effectively instantly (on an 1/a 3 -time-scale), we could just write
ds. The time for 50% of all defectively-infected cells to be those infected with mutant virus, t y3 , is then given via Y 3 = 0.5 and f 3 = 1 as
In the usual case where R m is significantly in excess of unity, we have the estimate
In this event, empirical data which permit an estimate of t y3 lead directly to assessment of the turnover rate for defectively-infected cells, a 3 . Notice, incidentally, that the approximate eqn (56) gives t y3 1 55 days for the parameter values in Fig. 2 , while yˆ1 m gets significantly larger than unity; all this is on a timescale of order 1/a 1 . So the contribution to f 3 from phase II is of general order of a 3 /a 1 , which is small. Overall, this points to the approximation of eqns (55) or (56) being reasonably accurate, so long as a 3 a 1 and R m d (which implies the requirement that R m be significantly larger than unity). Figure 2 bears this out: the early stages of y 3 do show some of the features of y 1 , but they settle relatively quickly on the time-scale of the y 3 dynamics.
(iv) Latently infected cells, y 2m . Here we have expressions for the absolute number of such cells infected with mutant virus, y 2m (t), and for the proportion of these mutant virus infected cells among all such latent cells, y 2 (t) = y 2m /(y 2 + y 2m ). These expressions are exactly as in eqns (52-56) above, with all subscripts ''3'' replaced by ''2''.
The analysis is, however, not usually as transparent as it can be for y 1m and y 3m . If a 2 is of the order of a 1 , so that latent cells infected with mutant virus come to preponderate within the ''phase I'' stage of the growth of y 1m , then analytic approximations to eqn (53) can be constructed; in essentials, the curve for Y 2 (t) behave similarly to that for Y 1 (t). At the opposite extreme, if a 2 is of the order of a 3 , then all the remarks just made about y 3 and y 3m pertain equally to y 2 and y 2m .
Most likely, however, a 2 will lie at values intermediate between a 1 and a 3 , such that nothing simple can be said about the dynamics of Y 2 (t). This is the case for the parameter values illustrated in Fig. 2 . (v) Total abundance of infected cells. Any interpretation of the dynamics of the total population of cells infected with mutant virus, y m (t) = y 1m (t) + y 2m (t) + y 3m (t), will depend significantly upon the factors which affect their initial relative abundances, and their asymptomatic relative abundances. For the total proportion of mutant-infected cells among all infected cells, Y(t) = y m (t)/ [y(t) + y m (t)], patterns will further depend on the initial relative abundances of the wildtype-infected cells. Insofar as a 3 is typically much smaller than a 1 and a 2 , defective cells are likely to be the most abundant of wild-type infected cells at t = 0. These cells, moreover, decay slowly (as e −a 3 t ), and so the rise in Y(t) is likely to be dominated by the asymptotic phase of y m (t); although Y 1 (t) saturates to unity relatively fast, by virtue of the fast decay in y 1 (t) (scaling as e −a 1 t ), this does not contribute much to the larger picture of all cells, dominated by the relatively large initial number and slow decay of y 3 -cells. Such general observations again help us to interpret the trends shown in the numerical simulations.
Experimental Results
Three patients were treated with the reverse transcriptase inhibitor Neverapine (NVP) (Shaw et al., in preparation) . Plasma virus load, CD4 cell counts and infected PBMC were measured sequentially after the start of therapy. We determined the amount of proviral DNA in peripherial blood mononuclear cells (PBMC), which gives the total proportion of HIV-infected PBMC. Using a limiting dilution assay for quantifying infectious units per 10 6 PBMC we determined the frequency of cells that harbour replication competent virus (either latently or actively replicating). In all three compartments (plasma virus, infectious PBMC and total infected PBMC) we quantify the proportions of NVP-sensitive wildtype virus and NVP-resistant mutant virus at day 0, 14, 28, 42 and 140 after initiating therapy (Fig. 3) . Table 1 gives information on viral load in terms of free virus and infected cells in 1 ml of blood in all three patients before start of therapy. Note that most HIV-infected PBMC appear to harbour replication defective virus; there are only between 15 and 30 infectious units within PBMC in 1 ml blood, but between 420 and 550 PBMC carrying HIV provirus.
In terms of our expanded model the data on proviral DNA provide information on the sum y 1 + y 2 + y 3 , whereas the cells harbouring replication competent virus describe y 1 + y 2 . Unfortunately, we do not have direct experimental data on y 1 or y 2 alone. In addition, we have to bear in mind that most HIV-infected cells and perhaps also most cells that produce plasma virus are in the lymph system and not in the peripherial blood.
After start of therapy, plasma virus load declines rapidly within the first 2 weeks and subsequently increased with the emergence of resistant virus. In patients 1625 and 1605 the initial decay of wildtype plasma virus between day 0 and 14 occurs with a half-life of 2.6 and 2.1 days respectively. Over the same time infected PBMC that harbour replication F. 3. Experimental data from three patients treated with the anti-HIV drug neverapine ''Plasma virus'' denotes free virus particles in 1 ml plasma. ''Infectious cells'' denotes PBMC harbouring replication competent HIV (per 1 ml blood). ''Provirus'' denotes number of PBMC with HIV proviral DNA (per 1 ml blood). The continuous line is drug-sensitive wildtype virus, whereas the broken line denotes drug-resistant mutant virus. ''Mutant frequency'' shows the rise of NVP-resistant mutant in the free virus population (continuous line), in the infectious PBMC population (broken line short dashes) and in the total infected PBMC population (broken line long dashes). In patients 1625 and 1624 resistant mutant rises first in the plasma population and then in the infected cell population (that has infectious virus). In patient 1605 the rise appears to be more or less simultaneous. In all three patients it takes much longer for the resistant mutant to establish itself in the provirus population. CD4 cell counts are shown per 1 ml blood. PBMC. For patient 1605 we obtain 7% which comes to about 1 in 10 6 PBMC. For patient 1624 these calculations are not possible because we lack measurements for day 14. Table 2 shows the relative abundance of total infected cells, actively infected cells and latently infected cells in the PBMC population.
NVP-resistant virus rises rapidly in all three patients in the free plasma virus population followed with a small delay in infected cells harbouring replication competent virus and with considerable delay in infected cells harbouring HIV provirus (Fig. 3) . At day 28 plasma virus contains 100% resistant virus in patients 1625, 76% in patient 1605 and 92% in patient 1624. It takes between 10 and 20 days for the resistant virus to reach 50% prevalence in the free virus population.
Using eqn (27) we can get a very crude estimate for the basic reproductive ratio of the resistant mutant under drug therapy. From eqn (27) we obtain R m = a/t NVP-resistant mutant rises only slowly in the DNA provirus population. After 140 days between 65% and 75% of infected PBMC harbour mutant provirus, which suggests that the turnover rate of infected PBMC at large is slow (see also Wei et al., 1995) . Using eqn (56) we obtain an average half-life of about 80 days for infected PBMC. The time lag between viral variants that emerge in the plasma RNA population and the proviral DNA population has also previously been noted by studies of HIV evolution in single patients (Simmonds et al., 1991) .
We can also obtain a very crude estimate of the probability that infection of a cell will result in defective or replication competent provirus. In analogy to eqn (31) we obtain 
Conclusions
We have developed a mathematical framework for studying the emergence of resistant mutant virus during drug treatment. We assume that mutant virus exists already before start of therapy and is held in a mutation-selection equilibrium. Without drug the fitness of wildtype is higher than the fitness of mutant, but continuous mutation of wildtype virus (together with replication of mutant virus) produces a small amount of mutant virus. The frequency of resistant mutant virus before therapy is given by v m /v = e/(1 − R m /R 0 ).
Here e is the mutation probability from wildtype to mutant, R 0 is the basic reproductive ratio (i.e. fitness) of wildtype virus and R m is the basic reproductive ratio of mutant virus-both before therapy. [We have also assumed that both wildtype and mutant have the same rate of virus production from infected cells, i.e. k = k m . Otherwise see eqn (9) .] If the fitness of the mutant is much smaller than that of the wildtype (R m R 0 ), then the frequency of the mutant virus is given by the mutation rate, e. If on the other hand, the fitnesses of wildtype and mutant are quite similar, then also the denominator in eqn (58) plays an important role. For example, if mutant and wildtype differ in a single point mutation, if the point mutation rate is 10 −4 , and if R m = 0.9R 0 , the pre-treatment frequency of resistant mutant is 10 −3 . Our analytic approximation for the emergence of resistance rests on the assumption that resistant virus rises as a consequence of increased abundance of target cells (McLean & Nowak, 1992) . From eqn (20) (58) is not valid. Our mathematical model in conjunction with data from three patient treated with the anti-HIV drug neverapine also provides new insights into the in vivo kinetics of HIV turnover. Together with previous work (Ho et al., 1995; Wei et al., 1995; Coffin, 1995; Nowak et al., 1995; Perelson et al., 1996) , the following picture has emerged: most of plasma virus is produced by cells with a half-life of about 1.5 to 2 days; latently infected cells have a half-life of about 10 to 20 days (but much more information is needed here to derive more accurate figures); most infected peripheral blood mononuclear cells (PBMC) harbour replication defective provirus and have a half-life of about 80 days; free plasma virus has a half-life of less than 6 hr.
It is still an open question how this kinetic picture of HIV infection ties in with the dynamics of disease progression. Virus load (i.e. the abundance of free virus in plasma) has been shown to be an important determinant of disease progression; patients with a high virus load soon after primary infection progress faster to AIDS than patients with a low virus load (Mellors et al., 1996; Ho, 1996) . Several factors, which can be host and virus specific, determine virus load, among these are the replication ability of the virus (Deacon et al., 1995) , the activation state of the CD4 cell population (note that HIV replicates predominantly in activated CD4 cells), and immune responsiveness, defined as the patients ability to mount an immune response to the virus (Nowak & Bangham, 1996) . Mathematical models of disease progression have to deal with the problem how the steady state of HIV-1 short-term kinetics is shifted toward higher virus load and lower CD4 cell abundance. Possible explanations include virus evolution (Nowak et al., 1990 (Nowak et al., , 1991 (Nowak et al., , 1995 deBoer & Boerlijst, 1994; Nowak & McMichael, 1995) , a slow destruction of the immune response against HIV, or increased levels of target cell activation (McLean & Nowak, 1992) .
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